PAUL D RUBIN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for PAUL D RUBIN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of PAUL D RUBIN. PAUL D RUBIN is a Sr. VP Clinical Dev. & CMO in XOMA Corp ($XOMA) and a President and CEO in CORNERSTONE THERAPEUTICS INC ($CRTX) and a EVP, Research & Development in MIRAGEN THERAPEUTICS, INC. ($SGNL).
Address: C/O CRITICAL THERAPEUTICS, INC. 60 WESTVIEW STREET LEXINGTON 02421 MA
Companies in which PAUL D RUBIN is an Insider
CORNERSTONE THERAPEUTICS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of PAUL D RUBIN: President and CEO
Holdings: 114,303 shares
Latest Transaction: Mar 22 2006
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Viridian Therapeutics, Inc.\DE
Industry: SERVICES-MEDICAL LABORATORIES [8071]
Position of PAUL D RUBIN: EVP, Research & Development
Holdings: 0 shares
Current Value: $0
Latest Transaction: Feb 08 2019
$MGEN Market Capitalization: $9.56M
$MGEN Previous Close: $10.55
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
XOMA Corp
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of PAUL D RUBIN: Sr. VP Clinical Dev. & CMO
Holdings: 326,601 shares
Current Value: $1,374,990
Latest Transaction: Mar 22 2016
$XOMA Market Capitalization: $25.10M
$XOMA Previous Close: $4.21
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of PAUL D RUBIN
Sentiment: All, CRTX, MGEN, XOMA
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 08 2019 | MGEN | MIRAGEN THERAPEUTI ... | RUBIN PAUL D | EVP, Research & Dev ... | Option Exercise | A | 2.96 | 87,000 | 257,520 | 87,000 | |
| Feb 02 2018 | MGEN | MIRAGEN THERAPEUTI ... | RUBIN PAUL D | EVP, Research & Dev ... | Option Exercise | A | 7.50 | 85,000 | 637,500 | 85,000 | |
| Feb 16 2017 | SGNL | MIRAGEN THERAPEUTI ... | RUBIN PAUL D | EVP, Research & Dev ... | Option Exercise | A | 11.01 | 87,500 | 963,375 | 87,500 | |
| Mar 22 2016 | XOMA | XOMA Corp | RUBIN PAUL D | Sr. VP Clinical Dev ... | Option Exercise | M | 0.00 | 12,141 | 0 | 0 | |
| Mar 22 2016 | XOMA | XOMA Corp | RUBIN PAUL D | Sr. VP Clinical Dev ... | Sell | S | 0.78 | 24,194 | 18,985 | 326,601 | 350.8 K to 326.6 K (-6.90 %) |
| Mar 22 2016 | XOMA | XOMA Corp | RUBIN PAUL D | Sr. VP Clinical Dev ... | Buy | M | 0.00 | 12,141 | 0 | 350,795 | 338.7 K to 350.8 K (+3.59 %) |
| Feb 29 2016 | XOMA | XOMA Corp | RUBIN PAUL D | Sr. VP Clinical Dev ... | Grant | A | 0.00 | 198,330 | 0 | 338,654 | 140.3 K to 338.7 K (+141.34 %) |